Ascentage Pharma is a global biopharmaceutical company engaged in developing novel therapies for hematological conditions. The company has multiple on-going clinical trials in Phase I and II that involve the use of novel drugs and investigational agents such as third-generation tyrosine kinase inhibitors olverembatinib, Bcl-2 inhibitor lisaftoclax; MDM2-p53 inhibitor alrizomadlin, ALK inhibitor APG-2449, dual Bcl-2/Bcl-xL inhibitor pelcitoclax, and EED inhibitors to address unmet medical needs.